• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ALTIVIA Appoints Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager

    4/8/24 12:44:00 PM ET
    $DOW
    $PFE
    Major Chemicals
    Industrials
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DOW alert in real time by email

    HOUSTON, April 8, 2024 /PRNewswire/ -- ALTIVIA today announced that it has named Scott Barnum as Director of Manufacturing and Dean Hale as Corporate Engineering Manager.

    Scott Barnum, Director of Manufacturing

    Mr. Barnum will oversee the process management, quality, and operations of ALTIVIA's Specialty and Oxide Chemicals' units. Mr. Hale will lead the development and management of ALTIVIA's Corporate Engineering Department.

    "We look forward to welcoming both Scott and Dean as ALTIVIA furthers its investment in growth, sustainability, and world-class operating performance," said Michael Jusbasche, ALTIVIA's Chief Executive Officer. "Their proven leadership and experience in the chemicals industry will fuel ALTIVIA's growth."

    Scott Barnum

    Mr. Barnum has 30 years of experience in the chemicals industry, including phosgenation, chlorination, sulfonation, and esterification processes. Prior to joining ALTIVIA, Mr. Barnum served as the Director of Manufacturing at Niacet Corporation, a division of Kerry Group, plc (OTC Markets KRYAY), an industry-leading manufacturer in food feed, and pharmaceutical additives. Mr. Barnum served as board member of the Buffalo Niagara Manufacturing Alliance, representing 194 member companies.

    During his career, Mr. Barnum has been recognized for his contributions to environmental, safety, and health management. Mr. Barnum holds a Bachelor of Science in Chemical Engineering from The State University of New York.

    Dean Hale

    Mr. Hale has spent the last 33 years in various engineering capacities in the chemicals industry, focused on process development, implementation, and optimization. He brings a breadth of industry experience in applications including petrochemicals, semiconductor chemicals, pharmaceuticals, and food additives. Prior to joining ALTIVIA, he most recently served as the Engineering Manager for Niacet Corporation, a division of Kerry Group, plc (OTC Markets: KRYAY), and has held various engineering and project management roles for DOW (NYSE:DOW) and Pfizer (NYSE:PFE).

    Mr. Hale has been a recipient of the Pfizer Innovation Award and the Teamwork Award, and Pharmacia's Outstanding Performance Recognition Award. Mr. Hale holds a Bachelor of Science in Chemical Engineering from Michigan State University and is certified as a Project Management Professional.

    Mr. Barnum's and Mr. Hale's leadership were instrumental in Niacet's winning the American Chemistry Council's (ACC) Company of the Year Award for outstanding environmental, safety, health, and security performance.

    About ALTIVIA

    Headquartered in Houston, Texas, privately held ALTIVIA was founded in 1986 and today operates four petrochemical and specialty chemical manufacturing facilities in Texas, Ohio, and West Virginia.

    • ALTIVIA Petrochemicals, with facilities in Haverhill, Ohio, is the third largest merchant producer of Phenol, Acetone, and alpha-methyl-styrene in the Americas.
    • ALTIVIA Specialty Chemicals, the largest producer of Phosgene derivative intermediates in the Americas, including chloroformates and acid chlorides, serving the pharmaceutical, organic peroxide, and agricultural markets from its operations in LaPorte, Texas.
    • ALTIVIA Ketones & Additives, a global leader and producer of ketones and carbinols at its facilities in Institute, West Virginia. This business was acquired from The Dow Chemical Company in 2019, and it serves the coatings, industrial and automotive lubricants, and adhesives industries.
    • ALTIVIA Oxide Chemicals specializes in custom production of various chemical intermediates serving surfactant, lubricant, and fuel additives markets. The production facility in Crosby, Texas, includes 31 reactors and distillation trains with ethoxylation, propoxylation and a range of organic reaction capabilities.

    For more information contact:

    Kelly Kimberly

    +1.713.822.7538

    [email protected] 

    Dean Hale, Corporate Engineering Manager

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/altivia-appoints-scott-barnum-as-director-of-manufacturing-and-dean-hale-as-corporate-engineering-manager-302110654.html

    SOURCE ALTIVIA

    Get the next $DOW alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DOW
    $PFE

    CompanyDatePrice TargetRatingAnalyst
    Dow Inc.
    $DOW
    8/14/2025$25.00Underperform → Neutral
    BofA Securities
    Dow Inc.
    $DOW
    8/5/2025$40.00Neutral → Buy
    Rothschild & Co Redburn
    Dow Inc.
    $DOW
    7/25/2025$32.00Outperform → In-line
    Evercore ISI
    Dow Inc.
    $DOW
    6/23/2025$22.00Market Perform → Underperform
    BMO Capital Markets
    Pfizer Inc.
    $PFE
    4/22/2025$24.00Neutral
    Cantor Fitzgerald
    Dow Inc.
    $DOW
    4/15/2025$28.00Buy → Underperform
    BofA Securities
    Dow Inc.
    $DOW
    4/4/2025$31.00Overweight → Neutral
    Analyst
    Dow Inc.
    $DOW
    1/7/2025$60.00 → $53.00Overweight → Neutral
    Piper Sandler
    More analyst ratings

    $DOW
    $PFE
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    October 25, 2024 - FDA Roundup: October 25, 2024

    For Immediate Release: October 25, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA updated the advisory for the outbreak of E. coli O157:H7. A specific ingredient has not yet been confirmed as the source of the outbreak, but most sick people report eating McDonald’s Quarter Pounder burgers. Investigators are working to deter

    10/25/24 2:48:21 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for HYMPAVZI issued to PFIZER INC

    Submission status for PFIZER INC's drug HYMPAVZI (ORIG-1) with active ingredient MARSTACIMAB-HNCQ has changed to 'Approval' on 10/11/2024. Application Category: BLA, Application Number: 761369, Application Classification:

    10/15/24 2:57:27 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    October 11, 2024 - FDA Approves New Treatment for Hemophilia A or B

    For Immediate Release: October 11, 2024 Today, the U.S. Food and Drug Administration approved Hympavzi (marstacimab-hncq) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors (neutralizing antibodies). “Today’s approval of Hympavzi pro

    10/11/24 2:12:15 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOW
    $PFE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Dow reports third quarter 2025 results

    MIDLAND, Mich., Oct. 23, 2025 /PRNewswire/ -- Dow (NYSE:DOW):  3Q25 FINANCIAL HIGHLIGHTS Net sales were $10.0 billion, down 8% year-over-year, reflecting declines in all operating segments. Sequentially, net sales were down 1%, as gains in Industrial Intermediates & Infrastructure were more than offset by declines in Packaging & Specialty Plastics and Performance Materials & Coatings.Volume decreased 1% year-over-year, as declines in Europe, the Middle East, Africa and India (EMEAI) were partly offset by gains in the U.S. and Canada and Asia Pacific. Sequentially, volume incre

    10/23/25 6:00:00 AM ET
    $DOW
    Major Chemicals
    Industrials

    Patient-Reported Outcomes from VERITAC-2 Clinical Trial Support Clinical Benefit of Vepdegestrant in Patients with ESR1-Mutated, ER+/HER2- Advanced or Metastatic Breast Cancer Previously Treated with Endocrine-Based Therapy

    – Data demonstrated that vepdegestrant maintained patients' quality of life for statistically significantly longer and delayed worsening of overall health, daily functioning, and symptoms, including pain, compared to fulvestrant –  NEW HAVEN, Conn., Oct. 20, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), today announced new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial (NCT05654623) evaluating vepdegestrant, which are being presented in a mini oral session at the 2025 European Society for Medical Oncology (ESMO) Congress. Vepdegestrant is a novel investigational PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader which is being de

    10/20/25 4:15:00 AM ET
    $ARVN
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer

    The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive prostate cancer with high-risk biochemical recurrence1 XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting Final results from the Phase 3 EMBARK study are being presented in a late-breaking oral session at ESMO 2025 and simultaneously published in The New England Journal of Medicine Pfizer Inc. (NYSE:PFE) and Astellas Pharma U.S. Inc. (Head of Commercial: Mike Petroutsas, "Astellas") tod

    10/19/25 4:15:00 AM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOW
    $PFE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Chairman & CEO Bourla Albert

    4 - PFIZER INC (0000078003) (Issuer)

    10/17/25 5:19:03 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chairman & CEO Bourla Albert

    4 - PFIZER INC (0000078003) (Issuer)

    10/16/25 7:52:44 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Taraporevala Cyrus

    4 - PFIZER INC (0000078003) (Issuer)

    10/2/25 4:56:13 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $DOW
    $PFE
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Blaylock Ronald E bought $499,072 worth of shares (19,457 units at $25.65), increasing direct ownership by 236% to 27,707 units (SEC Form 4)

    4 - PFIZER INC (0000078003) (Issuer)

    2/14/25 5:16:36 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Dial Debra L. bought $26,197 worth of shares (675 units at $38.81) (SEC Form 4)

    4 - DOW INC. (0001751788) (Issuer)

    2/11/25 4:15:26 PM ET
    $DOW
    Major Chemicals
    Industrials

    Director Banister Gaurdie E. Jr. bought $299,932 worth of shares (7,339 units at $40.87) (SEC Form 4)

    4 - DOW INC. (0001751788) (Issuer)

    12/17/24 4:59:47 PM ET
    $DOW
    Major Chemicals
    Industrials

    $DOW
    $PFE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Dow upgraded by BofA Securities with a new price target

    BofA Securities upgraded Dow from Underperform to Neutral and set a new price target of $25.00

    8/14/25 8:05:45 AM ET
    $DOW
    Major Chemicals
    Industrials

    Dow upgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn upgraded Dow from Neutral to Buy and set a new price target of $40.00

    8/5/25 7:03:19 AM ET
    $DOW
    Major Chemicals
    Industrials

    Dow downgraded by Evercore ISI with a new price target

    Evercore ISI downgraded Dow from Outperform to In-line and set a new price target of $32.00

    7/25/25 8:58:32 AM ET
    $DOW
    Major Chemicals
    Industrials

    $DOW
    $PFE
    SEC Filings

    View All

    Dow Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - DOW INC. (0001751788) (Filer)

    10/23/25 7:01:53 AM ET
    $DOW
    Major Chemicals
    Industrials

    SEC Form 8-K filed by Dow Inc.

    8-K - DOW INC. (0001751788) (Filer)

    9/8/25 4:07:22 PM ET
    $DOW
    Major Chemicals
    Industrials

    SEC Form 8-K filed by Dow Inc.

    8-K - DOW INC. (0001751788) (Filer)

    9/2/25 6:14:07 AM ET
    $DOW
    Major Chemicals
    Industrials

    $DOW
    $PFE
    Leadership Updates

    Live Leadership Updates

    View All

    Pfizer Reaches Landmark Agreement with U.S. Government to Lower Drug Costs for American Patients

    Voluntary agreement meets the President's four requests while also protecting the U.S. ecosystem responsible for America's leadership in delivering medical breakthroughs Agreement provides certainty from tariffs and clarity on pricing framework that furthers Pfizer's ability to expand investment in U.S.-based innovation and return manufacturing to the U.S. Pfizer to fully focus on delivering the next generation of cures, especially in cancer, obesity, vaccines, and inflammation and immunology Pfizer CEO Albert Bourla joins President Donald J. Trump and members of his Administration in White House event today Pfizer Inc. (NYSE:PFE) today announced a historic agreement with the T

    9/30/25 12:45:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dow announces results from 2025 Annual Stockholder Meeting

    Declares quarterly dividend of 70 cents per shareRichard K. Davis re-elected independent lead directorMIDLAND, Mich., April 10, 2025 /PRNewswire/ -- Dow (NYSE:DOW) is pleased to report the results of its 2025 Annual Meeting of Stockholders. Today stockholders elected Samuel R. Allen, Gaurdie E. Banister Jr., Wesley G. Bush, Richard K. Davis, Jerri DeVard, Debra L. Dial, Jeff M. Fettig, Jim Fitterling, Jacqueline C. Hinman, Rebecca B. Liebert, Luis Alberto Moreno, Jill S. Wyant, and Daniel W. Yohannes to the Company's Board of Directors for one-year terms. Stockholders approved

    4/10/25 4:15:00 PM ET
    $DOW
    Major Chemicals
    Industrials

    Dexcom Appoints Jon Coleman as Chief Commercial Officer

    DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced the appointment of Jon Coleman as chief commercial officer. In this role, Mr. Coleman will assume responsibility for Dexcom's global commercial organization, including global sales, marketing and customer experience. Mr. Coleman joins Dexcom with more than 30 years of global commercial leadership experience across multiple healthcare segments and channels. Mr. Coleman served as an executive officer of Masimo Corporation (NASDAQ:MASI), where he held roles of increasing responsibility across his fifteen-year tenure. This included serving as president of Masimo's commercial teams where he oversaw the consolid

    3/25/25 4:05:00 PM ET
    $DXCM
    $MASI
    $PFE
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Biotechnology: Pharmaceutical Preparations

    $DOW
    $PFE
    Financials

    Live finance-specific insights

    View All

    Dow reports third quarter 2025 results

    MIDLAND, Mich., Oct. 23, 2025 /PRNewswire/ -- Dow (NYSE:DOW):  3Q25 FINANCIAL HIGHLIGHTS Net sales were $10.0 billion, down 8% year-over-year, reflecting declines in all operating segments. Sequentially, net sales were down 1%, as gains in Industrial Intermediates & Infrastructure were more than offset by declines in Packaging & Specialty Plastics and Performance Materials & Coatings.Volume decreased 1% year-over-year, as declines in Europe, the Middle East, Africa and India (EMEAI) were partly offset by gains in the U.S. and Canada and Asia Pacific. Sequentially, volume incre

    10/23/25 6:00:00 AM ET
    $DOW
    Major Chemicals
    Industrials

    Pfizer Declares Fourth-Quarter 2025 Dividend

    Board of Directors approves quarterly cash dividend of $0.43 per share Pfizer Inc. (NYSE:PFE) today announced that its board of directors declared a $0.43 fourth-quarter 2025 dividend on the company's common stock, payable December 1, 2025, to holders of the Common Stock of record at the close of business on November 7, 2025. The fourth-quarter 2025 cash dividend will be the 348th consecutive quarterly dividend paid by Pfizer. About Pfizer: Breakthroughs That Change Patients' Lives At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discov

    10/9/25 4:30:00 PM ET
    $PFE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Dow declares quarterly dividend of 35 cents per share

    MIDLAND, Mich., Oct. 9, 2025 /PRNewswire/ -- Dow (NYSE:DOW) has declared a dividend of 35 cents per share, payable December 12, 2025, to shareholders of record on November 28, 2025. This marks the 457th consecutive dividend paid by the Company or its affiliates since 1912. About DowDow (NYSE:DOW) is one of the world's leading materials science companies, serving customers in high-growth markets such as packaging, infrastructure, mobility and consumer applications. Our global breadth, asset integration and scale, focused innovation, leading business positions and commitment to

    10/9/25 4:15:00 PM ET
    $DOW
    Major Chemicals
    Industrials

    $DOW
    $PFE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Dow Inc.

    SC 13G/A - DOW INC. (0001751788) (Subject)

    11/12/24 2:25:16 PM ET
    $DOW
    Major Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by Dow Inc.

    SC 13G/A - DOW INC. (0001751788) (Subject)

    11/4/24 11:51:32 AM ET
    $DOW
    Major Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by Dow Inc.

    SC 13G/A - DOW INC. (0001751788) (Subject)

    10/17/24 12:57:12 PM ET
    $DOW
    Major Chemicals
    Industrials